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We would like to thank Dr. Currie et al. for their
comments. They raise an important question: does
an asthma management strategy which incorpo-
rates adjustment of inhaled corticosteroid dose
according to an indirect measure of airway inﬂam-
mation such as bronchial hyperresponsiveness lead
to improvements in asthma control? The studies
included in the Cochrane reviews reported in our
overview did not incorporate such an approach.
Patients included in the trials contributing to the
Dose-Response Reviews were randomised to treat-
ment arms, which had a ﬁxed inhaled corticoster-
oid dose. Most of the studies included in the
starting dose review also used a ﬁxed dose
comparison. Those that assessed a step-down
approach used a ﬁxed time interval of between 1
week and 2 months before stepping down dose or
speciﬁed dose reductions according to pre-deﬁned
composite control scores based upon the experi-
ence of symptoms and measures of airway calibre.
The AMPUL study1 raises the possibility that
adopting a dose adjustment strategy that includes
assessment of bronchial hyperresponsiveness as
well as symptoms permits maintenance of asthma
control and reduces the frequency of exacerba-
tions. Indeed there is also evidence that non-
invasive direct assessment of airway inﬂammation
using sputum eosinophil counts to titrate inhaledee front matter & 2006 Elsevier Ltd. All rights reserve
med.2006.09.011corticosteroid dose can achieve reductions in
exacerbations.2 The data presented in the overview
of Cochrane reviews that have assessed inhaled
steroid dose-response characteristics for ﬁxed
dosing regimens conﬁrm a shallow dose-associated
variability of response in populations of asthma
subjects. As further trial data emerge it may be
that individually tailored treatment plans, incor-
porating inhaled steroid dose adjustment titrated
to biomarkers of airway inﬂammation as well as
traditional markers of control will form a part of
future asthma management recommmendations.
However, at present there are signiﬁcant practical
and logistic difﬁculties associated with performing
such measures and they are not likely to change
care for the majority of asthma patients in the near
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